Clinical Trial Update: Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SyB L-0501 in combination with rituximab for untreated low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma; results on effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SyB L-0501

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Low-grade B Cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated | Phase 2 | Status: COMPLETED | Results posted: 2016-04-27